Hypertension and hypoglycemia in a child with hepatoblastoma: a case report

Hepatoblastoma is the most common malignant tumor in the pediatric age group. It is treated with chemotherapy and surgery with excellent results. In majority of the cases ,the course of treatment is uncomplicated. Rarely there could be unexpected complications like hypertension due to hypersecretion of renin or severe hypoglycemia due to production of insulin like substances by tumor cells. These episodes can complicate the management of the case. We report a rare case of hepatoblastoma in an eight-year-old child who had both the complications. To the best of our knowledge, this is the first such case to be reported in literature

Outcome of children with Hodgkin's disease. A 10-year experience from a single institution in Kuwait

To evaluate the outcome of children with Hodgkin's disease over a period of Loyrs from a Single instituhon in Kuwait Sixty-three children with previously untreated Hodgkin's disease, who were diagnosed at the Pediatric Oncology Unit of Kuwait Cancer Control Centre, Shuwaikh, Kuwait from January 1998 to December 2007 were included in the study. All cases were proved by histopathology, and staging was carried out according to the Ann Arbor system. Our series included 37 [59%] males and 26 [41%] females with a median age of 10 years [range 3-15 years]. B symptoms were present in 20 [32%] children. Bulky disease was noted in 28 [44%] children, with stages III in 8 [13%] and IV in 12 [19%] children. Chemotherapy was administered as a primary treatment in 63 children. The median number of chemotherapy cycles given was 6 [range 2-8]. Radiotherapy was used in 40 [63%] children. Grade III hematological toxicity was observed in 23[37%] and grade IV in 14 [22%] children. Hypothyroidism was observed in 20 [32%] children. Fifty-five children achieved a complete remission [87%] and 2 children achieved a partial remission [3%] with an overall response rate of 90%. Three children achieved a progressive disease [5%] and response could not be evaluated in 3 [5%] children. At a median follow-up of 67 months [5.5 years], the overall survival was 91%. With moderate toxicity, combined modality therapy is effective in the treatment of childhood Hodgkin's disease